Report: Drugmakers improve R&D productivity

12/3/2012 | Reuters

Drugmakers are taking a targeted, smarter approach to research and development, getting more compounds through the approval process, but nagging commercialization issues remain, according to a Deloitte and Thomson Reuters report. The number of new drug approvals was up by about 30%, according to the annual report, but expected revenue from new drugs was lower. The average cost of developing a new drug hovered around $1.1 billion.

View Full Article in:

Reuters

Published in Brief: